Markets:

Overview

News

Currencies

International

Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about bluebird bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. ↗

September 26, 2024

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Via Investor's Business Daily

The Analyst Verdict: bluebird bio In The Eyes Of 5 Experts ↗

September 25, 2024

Via Benzinga

Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year ↗

September 24, 2024

Bluebird bio announces restructuring plans to reduce costs by 20% and achieve cash flow break-even by late 2025. The initiative includes a 25% workforce reduction and focuses on advancing key gene...

Via Benzinga

What 4 Analyst Ratings Have To Say About bluebird bio ↗

August 15, 2024

Via Benzinga

This Snowflake Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

August 15, 2024

Via Benzinga

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline ↗

June 17, 2024

With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.

Via InvestorPlace

Is Bluebird Bio Stock a Buy? ↗

May 16, 2024

It won't be easy for the company to bounce back.

Via The Motley Fool

Is Bluebird Bio Stock a Buy? ↗

April 15, 2024

This small biotech is struggling to fly -- and investors should probably steer clear.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 09, 2024

Via Benzinga

Better Buy: Bluebird Bio Vs. Novavax ↗

April 13, 2024

Who wins this face-to-face between two beaten-down biotechs?

Via The Motley Fool

Is This Beaten-Down Stock a Good Acquisition Target? ↗

April 11, 2024

This company has proven its innovative abilities, but that's not enough to outperform the market.

Via The Motley Fool

Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst ↗

March 29, 2024

Biotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain.

Via The Motley Fool

Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why ↗

March 28, 2024

The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia.

Via Investor's Business Daily

Peeling Back The Layers: Exploring bluebird bio Through Analyst Insights ↗

March 27, 2024

Via Benzinga

Peering Into bluebird bio's Recent Short Interest ↗

March 22, 2024

Via Benzinga

Is Bluebird Bio Stock a Buy Now? ↗

March 13, 2024

Are you feeling brave?

Via The Motley Fool

Forecasting The Future: 6 Analyst Projections For bluebird bio ↗

March 05, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 26, 2024

Via Benzinga

Earnings Scheduled For March 26, 2024 ↗

March 26, 2024

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.

Via Benzinga

Why Bluebird Bio Stock Flew Higher Than the Market Today ↗

March 18, 2024

The company was thrown a financial lifeline.

Via The Motley Fool

(BLUE) - Analyzing bluebird bio's Short Interest ↗

February 29, 2024

Via Benzinga

Why Bluebird Bio Stock Dived Into the Red on Tuesday ↗

March 05, 2024

The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation.

Via The Motley Fool

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

February 29, 2024

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Via Benzinga

Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug ↗

February 27, 2024

Both companies are working on treatments for genetic disorders.

Via Investor's Business Daily

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 27, 2024

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

Via Benzinga

If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today ↗

January 27, 2024

The answer hardly inspires confidence.

Via The Motley Fool

Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule ↗

January 17, 2024

FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the...

Via Benzinga

2 Red Flags for Bluebird Bio Stock ↗

January 10, 2024

The biotech's struggles may continue.

Via The Motley Fool

Better Risky Investment: Bluebird Bio vs. Shiba Inu ↗

January 03, 2024

Few investors dare to tread where the ice is known to be very thin.

Via The Motley Fool

Should You Invest in Bluebird Bio Right Now? ↗

December 26, 2023

After two December share price crashes, there's no evident cure for Bluebird Bio's ills.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

bluebird bio, Inc. - Common Stock (NQ:BLUE)

Headline News about bluebird bio, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today